LYL-132
- Generic Name
- LYL-132
Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2020-08-25
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Adaptimmune
- Target Recruit Count
- 12
- Registration Number
- NCT04526509
- Locations
- 🇸🇪
GSK Investigational Site, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath